Antimicrob Agents Chemother:长途跋涉也能导致耐药细菌的传播

2015-08-23 MedSci MedSci原创

在印度和中非短途学习的的瑞典交换生返回国内后,发现机体肠道微生物的耐药基因多样性增加,研究人员将文章发表在 Antimicrobial Agents and Chemotherapy。在这项研究中,研究人员发现:交换生体内的磺胺类耐药基因增加2.6倍,甲氧苄啶耐药基因增加7.7倍,β-内酰胺类耐药基因增加2.6倍。且这35名交换生之前并未有任何抗生素使用史和耐药史。在他们作为交换生学习之前他们体内

在印度和中非短途学习的的瑞典交换生返回国内后,发现机体肠道微生物的耐药基因多样性增加,研究人员将文章发表在 Antimicrobial Agents and Chemotherapy。


在这项研究中,研究人员发现:交换生体内的磺胺类耐药基因增加2.6倍,甲氧苄啶耐药基因增加7.7倍,β-内酰胺类耐药基因增加2.6倍。且这35名交换生之前并未有任何抗生素使用史和耐药史。在他们作为交换生学习之前他们体内的耐药基因也不明显,但是在他们学毕归来之时体内肠道耐药基因却如此明显。

这引发了大家对抗生素耐药性的强烈关注。瑞典优密欧大学传染控制科的Anders Johansson博士说道:“我是一名感染科医生,抗生素的使用使我可以治愈十年前无法治愈的患者,它具有十分强大的作用。”

但是Johansson博士对此十分怀疑,因为抗生素的滥用会产生耐药性,甚至导致超级细菌的产生。这是个十分严峻的问题。 患者入院时有可能会携带耐药细菌作为自身肠道菌群的一部分,即使使用抗生素,但是耐药细菌数目非常多,且耐药性十分强大,使得耐药细菌无法清除,且患者的治疗过程十分困难。

事实上,交换生在旅行之前或在旅行期间都从未使用抗生素,但体内的耐药基因的确增加。研究人员认为,可能是饮用水被污染,或食物中还有耐药细菌等,导致交换生体内耐药基因增加。

Johansson博士说:“收集耐药基因的样本很简单。我们要求去海外交流的学生在出国前后都留取大便标本。但是与以往研究不同的是,我们如今使用宏观基因组测序的方法。因此我们可以探究每一个学生大便标本的所有微生物群,并发现所有的耐药基因。”博士认为,为了减少民众对抗生素的耐药性,首先要进行完善医疗系统和健全相应体制。为了避免耐药细菌的扩散,旅游或其他各种原因出国的民众在相应活动结束后应立即回到自己的国家。

原始出处:

Bengtsson-Palme J, Angelin M, Huss M, Kjellqvist S, Kristiansson E, Palmgren H, Larsson DG, Johansson A.The human gut microbiome as a transporter of antibiotic resistance genes between continents.Antimicrob Agents Chemother. 2015 Aug 10.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084132, encodeId=577f2084132be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 28 03:50:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779480, encodeId=e38f1e7948035, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Apr 30 16:50:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779542, encodeId=423a1e7954294, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 13 17:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724664, encodeId=fb711e2466406, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Fri Feb 12 09:50:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857359, encodeId=8d36185e3596e, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 11 04:50:00 CST 2016, time=2016-01-11, status=1, ipAttribution=)]
    2016-03-28 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084132, encodeId=577f2084132be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 28 03:50:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779480, encodeId=e38f1e7948035, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Apr 30 16:50:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779542, encodeId=423a1e7954294, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 13 17:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724664, encodeId=fb711e2466406, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Fri Feb 12 09:50:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857359, encodeId=8d36185e3596e, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 11 04:50:00 CST 2016, time=2016-01-11, status=1, ipAttribution=)]
    2016-04-30 grace5700
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084132, encodeId=577f2084132be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 28 03:50:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779480, encodeId=e38f1e7948035, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Apr 30 16:50:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779542, encodeId=423a1e7954294, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 13 17:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724664, encodeId=fb711e2466406, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Fri Feb 12 09:50:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857359, encodeId=8d36185e3596e, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 11 04:50:00 CST 2016, time=2016-01-11, status=1, ipAttribution=)]
    2015-12-13 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084132, encodeId=577f2084132be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 28 03:50:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779480, encodeId=e38f1e7948035, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Apr 30 16:50:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779542, encodeId=423a1e7954294, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 13 17:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724664, encodeId=fb711e2466406, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Fri Feb 12 09:50:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857359, encodeId=8d36185e3596e, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 11 04:50:00 CST 2016, time=2016-01-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2084132, encodeId=577f2084132be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 28 03:50:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779480, encodeId=e38f1e7948035, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sat Apr 30 16:50:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779542, encodeId=423a1e7954294, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 13 17:50:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724664, encodeId=fb711e2466406, content=<a href='/topic/show?id=808e8040e24' target=_blank style='color:#2F92EE;'>#耐药细菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80407, encryptionId=808e8040e24, topicName=耐药细菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c3133650204, createdName=lingqf, createdTime=Fri Feb 12 09:50:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857359, encodeId=8d36185e3596e, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 11 04:50:00 CST 2016, time=2016-01-11, status=1, ipAttribution=)]

相关资讯

致命“浪漫病”:我们只能依靠50年前的药物吗?

段子手们喜欢把人类这个物种分为普通、文艺和特二儿等类型。从一种与人类同生共长、上演了上万年爱恨情仇的病菌角度来看,这种分类也不无道理。今天要侃一侃的是颇具“文艺范儿”的一种病菌及其导致的“浪漫病”。 “文艺范儿”的古老病菌 这种病可能是历史上极少数和“浪漫”有关联的疾病:18-19世纪,欧洲很多文学青年崇尚它,因为患上这种病的人,通常都拥有消瘦的身材、忧郁的眼神、还会不时咳嗽,掩住

Nat Commun:抗生素对儿童发育有深远影响

纽约大学Langone医学中心的研究人员在六月三十日的Nature Communications杂志上发表文章指出,常用抗生素会对儿童发育产生深远的影响。研究显示,两类广泛使用的抗生素会让雌性小鼠体重增加、骨骼增大。此外,这两种抗生素破坏了机体的肠道微生物组(无数肠道菌组成的群体)。研究人员对小鼠进行了三个疗程的抗生素处理,分别使用了阿莫西林、泰乐菌素(代表大环内酯类抗生素)和它们的混合物。这项研

未来,细菌将为我们带来什么

研究的带头人,麻省理工学院(MIT)的Timothy K. Lu and Christopher Voigt和他的同事们表示该研究可能为检测肠道微生物及相关药物的发展铺平了道路。去年,今日医学新闻报道,纳什维尔范德堡大学研究人员的一项研究详细阐述了如何修饰和调整大肠杆菌,以减少小鼠的食物摄入量和肥胖程度。然而,麻省理工学院的医疗团队注意到,肠道内不存在大肠杆菌,肠道内的大肠杆菌在几天内就可以被清除

实用!抗生素的不良反应汇总

一、β内酰胺类抗生素的不良反应  (一)、青霉素类 青霉素类是通过抑制菌体细胞壁的合成而发挥杀菌作用。因人体细胞无细胞壁,青霉素对其几乎无影响。又因青霉素抗菌谱很广。所以深受患者欢迎。成为临床最常用的抗生素之一。但由于近年来大剂量、高浓度使用青霉素现象增多,其不良反应屡见发生。青霉素常见的不良反应有:1、过敏反应:较常见,包括荨麻疹等各类皮疹、白细胞减少、间质性肾炎、哮喘发作等和血清病型反应;

PNAS:科学家阐明抵御肺结核的新型抗生素靶点

最近来自苏赛克斯大学等处的科学家通过研究揭开了引发肺结核发生的结核杆菌致病的关键过程,相关研究刊登于国际杂志PNAS上,该研究或为开发抵御肺结核发生的新型抗生素提供思路。肺结核是世界上头号传染性疾病,其每年会引发150万人死亡,引发结核的结核分枝杆菌据估计在全球三分之一的人群机体中都存在,尽管活动性的肺结核仅在十分之一的个体中发生。尽管结核病变可以治愈,但细菌耐药性也在不断产生,目前科学家们面临的